14-3-3ζ as a prognostic marker and therapeutic target for cancer

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 12, 2010, Pages 1343-1354

  Neal, Christopher L ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

14 3 3 zeta; apoptosis; cancer; chemoresistance; prognostic marker

Indexed keywords

14 3 3 ZETA PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CISPLATIN; DIFOPEIN; DOXIRUBICIN; EPIRUBICIN; PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

ASTROCYTOMA; BREAST CANCER; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL DEATH; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG TARGETING; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG CANCER; MENINGIOMA; MOUTH CANCER; NEOPLASM; PANCREAS CANCER; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; STOMACH CANCER; TREATMENT OUTCOME;

14-3-3 PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78249285952     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.531011     Document Type: Review

References (107)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
2. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16(3):203-13
3. Kjarland E, Keen TJ, Kleppe R. Does isoform diversity explain functional differences in the 14-3-3 protein family? Curr Pharm Biotechnol 2006;7(3):217-23
4. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol 2006;16(3):162-72
5. Moore BW, Perez VJ. Specific acidic proteins of the nervous system. In: Carlson F, editor, Physiological and biochemical aspects of nervous integration. Englewood Cliffs, New Jersey, Prentice-Hall; 1967. p. 343-59
6. Gardino AK, Smerdon SJ, Yaffe MB. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol 2006;16(3):173-82
7. Chaudhri M, Scarabel M, Aitken A. Mammalian and yeast 14-3-3 isoforms form distinct patterns of dimers in vivo. Biochem Biophys Res Commun 2003;300(3):679-85
8. Aitken A. Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation. Chromosome location of mammalian isoforms and variants. Plant Mol Biol 2002;50(6):993-1010
9. Shen YH, Godlewski J, Bronisz A, et al. Significance of 14-3-3 self-dimerization for phosphorylation-dependent target binding. Mol Biol Cell 2003;14(11):4721-33
10. Tzivion G, Luo Z, Avruch J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 1998;394(6688):88-92
11. Yaffe MB, Rittinger K, Volinia S, et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 1997;91(7):961-71
12. Rittinger K, Budman J, Xu J, et al. Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell 1999;4(2):153-66
13. Masters SC, Pederson KJ, Zhang L, et al. Interaction of 14-3-3 with a nonphosphorylated protein ligand, exoenzyme S of Pseudomonas aeruginosa. Biochemistry 1999;38(16):5216-21
14. Han DC, Rodriguez LG, Guan JL. Identification of a novel interaction between integrin beta1 and 14-3-3beta. Oncogene 2001;20(3):346-57
15. Obsilova V, Herman P, Vecer J, et al. 14-3-3zeta C-terminal stretch changes its conformation upon ligand binding and phosphorylation at Thr232. J Biol Chem 2004;279(6):4531-40
16. Messaritou G, Grammenoudi S, Skoulakis EM. Dimerization is essential for 14-3-3zeta stability and function in vivo. J Biol Chem 2010;285(3):1692-700
17. Ellis JJ, Valencia TG, Zeng H, et al. CaM kinase IIdeltaC phosphorylation of 14-3-3beta in vascular smooth muscle cells: activation of class II HDAC repression. Mol Cell Biochem 2003;242(1-2): 153-61
18. Tsuruta F, Sunayama J, Mori Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004;23(8):1889-99
19. Van Hemert MJ, Niemantsverdriet M, Schmidt T, et al. Isoform-specific differences in rapid nucleocytoplasmic shuttling cause distinct subcellular distributions of 14-3-3sigma and 14-3-3zeta. J Cell Sci 2004;117(Pt 8):1411-20
20. Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010;70(6):2339-49
21. Obsilova V, Silhan J, Boura E, et al. 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res 2008;57(Suppl 3): S11-21
22. Aitken A, Ellis CA, Harris A, et al. Kinase and neurotransmitters. Nature 1990;344(6267):594
23. Jin J, Smith FD, Stark C, et al. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 2004;14(16):1436-50
24. Pozuelo Rubio M, Geraghty KM, Wong BH, et al. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J 2004;379(Pt 2):395-408
25. Wilker E, Yaffe MB. 14-3-3 Proteins-a focus on cancer and human disease. J Mol Cell Cardiol 2004;37(3):633-42
26. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009;19(1):16-23
27. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006;16(3):183-92
28. Pozuelo Rubio M, Peggie M, Wong BH, et al. 14-3-3s regulate fructose-2, 6-bisphosphate levels by binding to PKB-phosphorylated cardiac fructose-2, 6-bisphosphate kinase/phosphatase. EMBO J 2003;22(14):3514-23
29. Santoro MM, Gaudino G, Marchisio PC. The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell 2003;5(2):257-71
30. Suzuki A, Hirata M, Kamimura K, et al. aPKC acts upstream of PAR-1b in both the establishment and maintenance of mammalian epithelial polarity. Curr Biol 2004;14(16):1425-35
31. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3(12):931-43
32. Subramanian RR, Masters SC, Zhang H, Fu H. Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis. Exp Cell Res 2001;271(1):142-51
33. Aitken A, Baxter H, Dubois T, et al. Specificity of 14-3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans 2002;30(4):351-60
34. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000;19(46):5298-302
35. Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 2002;21(15):2418-24
36. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000;97(11):6049-54
37. Yang HY, Wen YY, Chen CH, et al. 14-3-3sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003;23(20):7096-107
38. Li Z, Liu JY, Zhang JT. 14-3-3sigma, the double-edged sword of human cancers. Am J Transl Res 2009;1(4):326-40
39. Sinha P, Kohl S, Fischer J, et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000;21(14):3048-57
40. Vazquez A, Grochola LF, Bond EE, et al. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 2010;70(1):172-80
41. Sugiyama A, Miyagi Y, Komiya Y, et al. Forced expression of antisense 14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis 2003;24(9):1549-59
42. Takihara Y, Matsuda Y, Hara J. Role of the beta isoform of 14-3-3 proteins in cellular proliferation and oncogenic transformation. Carcinogenesis 2000;21(11):2073-7
43. Freed E, McCormick F, Ruggieri R. Proteins of the 14-3-3 family associate with Raf and contribute to its activation. Cold Spring Harb Symp Quant Biol 1994;59:187-93
44. Pallas DC, Fu H, Haehnel LC, et al. Association of polyomavirus middle tumor antigen with 14-3-3 proteins. Science 1994;265(5171):535-7
45. Reuther GW, Fu H, Cripe LD, et al. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science 1994;266(5182):129-33
46. Yoshida K, Yamaguchi T, Natsume T, et al. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005;7(3):278-85
47. Seimiya H, Sawada H, Muramatsu Y, et al. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 2000;19(11):2652-61
48. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996;87(4):619-28
49. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96(6):857-68
50. Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007;282(15):11221-9
51. Tian Q, Feetham MC, Tao WA, et al. Proteomic analysis identifies that 14-3-3ζ interacts with beta-catenin and facilitates its activation by Akt. Proc Natl Acad Sci USA 2004;101(43):15370-5
52. Li S, Resnicoff M, Baserga R. Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem 1996;271(21):12254-60 (Pubitemid 26160887)
53. Spence SL, Dey BR, Terry C, et al. Interaction of 14-3-3 proteins with the insulin-like growth factor I receptor (IGFIR): evidence for a role of 14-3-3 proteins in IGFIR signaling. Biochem Biophys Res Commun 2003;312(4):1060-6
54. Nellist M, Goedbloed MA, de Winter C, et al. Identification and characterization of the interaction between tuberin and 14-3-3zeta. J Biol Chem 2002;277(42):39417-24
55. Shumway SD, Li Y, Xiong Y. 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J Biol Chem 2003;278(4):2089-92
56. Neal CL, Yao J, Yang W, et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009;69(8):3425-32
57. Zang L, Palmer Toy D, Hancock WS, et al. Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. J Proteome Res 2004;3(3):604-12
58. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008;27(9):1315-19
59. Li Z, Zhao J, Du Y, et al. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 2008;105(1):162-7
60. Matta A, Bahadur S, Duggal R, et al. Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 2007;7:169
61. Bajpai U, Sharma R, Kausar T, et al. Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers 2008;23(4):231-7
62. Ralhan R, Desouza LV, Matta A, et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009;8(1):300-9
63. Danes CG, Wyszomierski SL, Lu J, et al. 14-3-3zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008;68(6):1760-7
64. Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002;62(22):6740-9
65. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350(14):1430-41
66. Lu J, Guo H, Treekitkarnmongkol W, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009;16(3):195-207
67. Matta A, DeSouza LV, Shukla NK, et al. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 2008;7(5):2078-87
68. Fan T, Li R, Todd NW, et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007;67(16):7901-6
69. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002;99(20):12963-8
70. Garnis C, Coe BP, Ishkanian A, et al. Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 2004;39(1):93-8
71. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008;1:3
72. Lin M, Morrison CD, Jones S, et al. Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J Cancer 2009;125(3):603-11
73. Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16(2):214-18
74. Frasor J, Chang EC, Komm B, et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006;66(14):7334-40
75. Maxwell SA, Li Z, Jaya D, et al. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009;284(33):22379-89
76. Chatterjee D, Goldman M, Braastad CD, et al. Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. Int J Oncol 2004;25(2):503-9
77. Andrews RK, Du X, Berndt MC. The 14-3-3zeta-GPIb-IX-V complex as an antiplatelet target. Drug News Perspect 2007;20(5):285-92
78. Altar CA, Vawter MP, Ginsberg SD. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009;34(1):18-54
79. Watanabe K, Thandavarayan RA, Gurusamy N, et al. Role of 14-3-3 protein and oxidative stress in diabetic cardiomyopathy. Acta Physiol Hung 2009;96(3):277-87
80. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
81. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004;101(7):1892-7
82. Qi W, Martinez JD. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 2003;160(2):217-23
83. Ge F, Lu XP, Zeng HL, et al. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res 2009;8(6):3006-19
84. Guo J, Fisher KA, Darcy R, et al. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst 2010;6(7):1143-61
85. Wang B, Yang H, Liu YC, et al. Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 1999;38(38):12499-504
86. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem 2001;276(48):45193-200
87. Masters SC, Subramanian RR, Truong A, et al. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans 2002;30(4):360-5
88. Dong S, Kang S, Lonial S, et al. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 2008;22(3):572-7
89. Cao W, Yang X, Zhou J, et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis 2010;15(2):230-41
90. Du Y, Masters SC, Khuri FR, Fu H. Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay. J Biomol Screen 2006;11(3):269-76
91. Wu H, Ge J, Yao SQ. Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. Angew Chem Int Ed Engl 2010;49(37):6528-32
92. Cullere X, Rose P, Thathamangalam U, et al. Serine 257 phosphorylation regulates association of polyomavirus middle T antigen with 14-3-3 proteins. J Virol 1998;72(1):558-63
93. Ashihara E, Kawata E, Maekawa T. Future prospect of RNA interference for cancer therapies. Curr Drug Targets 2010;11(3):345-60
94. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3(12):1011-22
95. Qi W, Liu X, Qiao D, Martinez JD. Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer 2005;113(3):359-63
96. Shen J, Person MD, Zhu J, et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004;64(24):9018-26
97. Lu B, Xu J, Zhu Y, et al. Systemic analysis of the differential gene expression profile in a colonic adenoma-normal SSH library. Clin Chim Acta 2007;378(1-2): 42-7
98. Sharma R, Samantaray S, Shukla NK, Ralhan R. Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics 2003;81(5):481-8
99. Jang JS, Cho HY, Lee YJ, et al. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 2004;14(10):491-9
100. Arora S, Matta A, Shukla NK, et al. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42(2):97-108
101. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008;7(6):1162-73
102. Liang S, Xu Y, Shen G, et al. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 2009;30(23):4152-62
103. Yang X, Cao W, Lin H, et al. Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci 2009;276(1-2): 54-9
104. Cao L, Cao W, Zhang W, et al. Identification of 14-3-3 protein isoforms in human astrocytoma by immunohistochemistry. Neurosci Lett 2008;432(2):94-9
105. Liu Y, Tian RF, Li YM, et al. The expression of seven 14-3-3 isoforms in human meningioma. Brain Res 2010;1336:98-102
106. Janssen JJ, Klaver SM, Waisfisz Q, et al. Identification of genes potentially involved in disease transformation of CML. Leukemia 2005;19(6):998-1004
107. Huber E, Vlasny D, Jeckel S, et al. Gene profiling of cottontail rabbit papillomavirus-induced carcinomas identifies upregulated genes directly involved in stroma invasion as shown by small interfering RNA-mediated gene silencing. J Virol 2004;78(14):7478-89